Abstract
The c-Myc and human telomerase reverse transcriptase gene (hTERT) gene are frequently deregulated and overexpressed in malignancy. hTERT activity is induced by c-Myc and strategies designed to inhibit c-Myc expression in cancer cells may have considerable therapeutic value. We designed and used a short hairpin RNA to inhibit c-Myc expression in Colo 320 cells and validated its effect on cell proliferation. In this study, four c-Myc-shRNA expression vectors were constructed and introduced into Colo 320 cells. The effects of c-Myc silencing on tumor cell growth was assessed by soft agar assay and DNA synthesis experiments. The expressions of c-Myc and hTERT were also assessed by real-time reverse transcription-polymerase chain reaction and Western blot analysis. Upon transient transfection with plasmid encoding shRNA, it was found that expression of c-Myc and hTERT decreased in shRNA-transfected cells. The downregulation of c-Myc and hTERT inhibited cell growth, shortened telomere lengths, and suppressed telomerase activity. In conclusion, our findings demonstrate that shRNA of c-Myc can inhibit the DNA replication in Colo 320 cells effectively and reduce telomere length and telomerase activity, therefore, it could be used as a new potential anticancer tool for therapy of human colon cancer.
Highlights
The corresponding author submitted this article [1] to Journal of Experimental and Clinical Cancer Research this article had been accepted and previously published by Cancer Biotherapy & Radiopharmaceuticals [2]
Since it has been brought to the attention of all authors that duplicate submission and publication have taken place the decision has been made to retract the article published in Journal of Experimental and Clinical Cancer Research
The authors are deeply sorry for any inconvenience this may have caused to the editorial staff and readers
Summary
The corresponding author submitted this article [1] to Journal of Experimental and Clinical Cancer Research this article had been accepted and previously published by Cancer Biotherapy & Radiopharmaceuticals [2]. Address: 1Center of Experimental Medicine, Wuhan No.1 Hospital, Wuhan, 430022, PR China, 2Department of Pathogentic Biology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, PR China and 3Brain Research Center, University of British Columbia, Vancouver, BC, Canada
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have